Skip to main content

Seeing Market Shift, Invitrogen to Exclusively Distribute Blue Heron's Synthetic Gene Products

NEW YORK (GenomeWeb News) — Invitrogen, saying it sees more researchers moving toward using synthetic genes over clones, today said it will exclusively distribute Blue Heron's synthetic gene products.
Through the agreement, Invitrogen said it will make an undisclosed investment in Blue Heron in exchange for exclusive worldwide distribution rights for the firm’s GeneMaker platform.
The agreement also allows the companies to co-develop new products and services, although Invitrogen did not offer more specifics about those plans.
According to Invitrogen, the synthetic gene platform made by Bothell, Wash-based Blue Heron can “synthesize any gene sequence,” making it “ideal for the synthetic biology market.”
Invitrogen said it believes the alliance will allow it to offer enhanced drug-discovery capabilities to its pharmaceutical and biotech clients.
Financial terms of the agreement were not disclosed.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.